Live Analyst Rating Changes 2419 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Ryskin
BofA
Michael Ryskin
Wall Street Analyst
★★☆☆☆
#1981
on 13Foresight · ranked by our own returns
47%
Success Rate
-3.1%
Average Return
24 of 51 calls profitable · -6.2% vs benchmark
📈 Across the calls we could measure, roughly 47% of Michael Ryskin's ratings turned a profit when each position was held for 1 year — averaging -3.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

137 Buy 77 Hold 36 Sell
Michael's Stock Coverage 38 ratings · 2026-06-24
Company Date Position Consensus Price Target 1-Yr Return
ZTS
Zoetis
Jun 16, 2026 HOLD Buy
+75.8% avg upside
22 analysts
$108.00
40.48% Upside
-3.3%
DHR
Danaher
Jun 11, 2026 BUY Strong Buy
+20.8% avg upside
45 analysts
$270.00
50.94% Upside
-1.0%
CRL
Charles River Labs
Jun 05, 2026 BUY Strong Buy
+11.5% avg upside
34 analysts
+0.5%
ELAN
Elanco Animal Health
Jun 05, 2026 BUY Strong Buy
+28.0% avg upside
18 analysts
$32.00
38.12% Upside
+2.5%
PAHC
Phibro Animal Health
Jun 05, 2026 SELL Hold
+21.1% avg upside
10 analysts
$38.00
24.53% Upside
+0.5%
BRKR
Bruker
Jun 02, 2026 BUY Buy
-4.1% avg upside
22 analysts
$65.00
17.90% Upside
-4.5%
WST
West Pharmaceutical Services
Jun 02, 2026 BUY Strong Buy
+4.7% avg upside
17 analysts
+5.6%
WAT
Waters
Jun 02, 2026 HOLD Strong Buy
+2.9% avg upside
30 analysts
$400.00
11.94% Upside
-3.6%
TMO
Thermo Fisher
Jun 02, 2026 BUY Strong Buy
+26.2% avg upside
38 analysts
$630.00
34.27% Upside
-2.5%
A
Agilent
Jun 02, 2026 BUY Strong Buy
+3.9% avg upside
32 analysts
$155.00
22.43% Upside
-7.9%
ICLR
Icon
Jun 01, 2026 SELL Strong Buy
+26.7% avg upside
25 analysts
$125.00
12.32% Downside
-3.4%
TEM
Tempus AI, Inc. Class A
Jun 01, 2026 HOLD Strong Buy
+39.6% avg upside
19 analysts
$64.00
31.67% Upside
-4.2%
ALGN
Align Tech
May 27, 2026 SELL Strong Buy
+65.0% avg upside
21 analysts
$175.00
3.77% Upside
-4.9%
RVTY
Revvity
May 14, 2026 HOLD Buy
+5.5% avg upside
23 analysts
+9.6%
TXG
10x Genomics
May 14, 2026 HOLD Buy
-22.5% avg upside
18 analysts
+48.1%
ILMN
Illumina
May 14, 2026 SELL Buy
-11.2% avg upside
30 analysts
$100.00
39.29% Downside
-13.1%
QGEN
Qiagen
May 13, 2026 BUY Buy
+14.6% avg upside
23 analysts
$49.00
31.80% Upside
·
IQV
IQVIA Holdings
May 13, 2026 BUY Strong Buy
+32.2% avg upside
38 analysts
$245.00
43.09% Upside
-2.7%
CAI
Caris Life Sciences, Inc.
May 13, 2026 BUY Buy
+61.9% avg upside
20 analysts
$28.00
59.11% Upside
+12.2%
ALMR
Alamar Biosciences, Inc.
May 12, 2026 HOLD Strong Buy
+31.2% avg upside
5 analysts
$27.00
17.76% Upside
·
MTD
Mettler-Toledo
May 11, 2026 BUY Buy
+1.8% avg upside
18 analysts
+7.9%
MYGN
Myriad Genetics
May 07, 2026 SELL Hold
+310.8% avg upside
24 analysts
+4.4%
SDGR
Schrodinger
May 07, 2026 BUY Strong Buy
+85.4% avg upside
14 analysts
+8.8%
GH
Guardant Health
May 07, 2026 BUY Strong Buy
-5.5% avg upside
30 analysts
$135.00
3.18% Upside
+42.5%
EVO
Evotec AG
May 07, 2026 SELL Buy
+278.7% avg upside
9 analysts
+5.9%
FTRE
Fortrea Holdings Inc.
May 06, 2026 SELL Buy
-7.3% avg upside
11 analysts
$9.50
42.34% Downside
+14.2%
IDXX
Idexx Laboratories
May 05, 2026 HOLD Buy
+33.5% avg upside
17 analysts
$660.00
21.94% Upside
-0.2%
NEO
NeoGenomics
Apr 29, 2026 HOLD Strong Buy
+34.7% avg upside
17 analysts
$11.00
4.03% Downside
+24.4%
DGX
Quest Diagnostics
Apr 21, 2026 BUY Buy
-13.0% avg upside
33 analysts
$225.00
14.19% Upside
-3.5%
LH
Labcorp Holdings
Apr 07, 2026 BUY Strong Buy
+1.1% avg upside
36 analysts
$295.00
14.15% Upside
-1.2%
STVN
Stevanato Group
Mar 04, 2026 BUY Strong Buy
+58.4% avg upside
13 analysts
$28.00
65.92% Upside
-2.3%
AVTR
Avantor
Feb 11, 2026 HOLD Buy
+52.7% avg upside
26 analysts
$11.00
16.61% Upside
-2.2%
MRVI
Maravai Lifesciences Holdings
Mar 03, 2025 BUY Strong Buy
+167.0% avg upside
17 analysts
$8.00
49.03% Upside
+22.2%
CERT
Certara
Feb 27, 2025 BUY Buy
+139.8% avg upside
21 analysts
$17.00
214.81% Upside
-42.9%
DNA
Ginkgo Bioworks Holdings
Jul 18, 2024 SELL Sell
-11.5% avg upside
5 analysts
$10.00
12.91% Upside
+16.4%
SDCCQ
SmileDirectClub
Aug 08, 2023 SELL Hold
+513999900.0% avg upside
10 analysts
$0.40
39999900.00% Upside
·
ABSI
AbSci
Apr 24, 2023 SELL Strong Buy
+32.2% avg upside
18 analysts
$2.40
67.57% Downside
-192.3%
RXRX
Recursion Pharmaceuticals
Apr 18, 2022 HOLD Buy
+149.6% avg upside
12 analysts
$10.00
216.54% Upside
-9.0%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Michael Ryskin — Frequently Asked Questions
How accurate are Michael Ryskin's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Michael's ratings were profitable over a one-year hold, with an average return of -3.1% per rating, or -6.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael Ryskin is currently ranked #1981 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on ZTS, DHR, CRL, ELAN, PAHC, BRKR, WST, WAT, TMO, A, ICLR, TEM and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.